Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. 1978

A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve

A double-blind crossover study on the effects of deanol and lithium carbonate was conducted on a sample of 29 chronic schizophrenic patients with tardive dyskinesia. In addition to his usual treatment with different neuroleptics, each patient received during an 8-week period either deanol, lithium carbonate or placebo. A 4-week wash-out period was inserted between each of the 8-week periods of experimental treatment of the tardive dyskinesia. The administration of either deanol, lithium carbonate or placebo added to the neuroleptic treatment did not produce a statistically significant improvement of tardive dyskinesia in our patient population as a whole. Favorable and unfavorable responses are discussed.

UI MeSH Term Description Entries
D008094 Lithium An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER. Lithium-7,Lithium 7
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003642 Deanol An antidepressive agent that has also been used in the treatment of movement disorders. The mechanism of action is not well understood. Dimethylaminoethanol,Astyl,Deanol Bisorcate,Demanol,Demanyl,Dimethylethanolamine,N,N-Dimethyl-2-hydroxyethylamine,N,N-Dimethylethanolamine,Tonibral,Bisorcate, Deanol,N,N Dimethyl 2 hydroxyethylamine
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias

Related Publications

A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
November 2001, Archives of general psychiatry,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
September 1976, Archiv fur Psychiatrie und Nervenkrankheiten,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
May 1978, JAMA,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
November 2007, The Journal of clinical psychiatry,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
March 1981, The Australian and New Zealand journal of psychiatry,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
September 2001, The American journal of psychiatry,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
December 1982, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
November 1979, Psychopharmacology,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
August 1992, Psychiatry research,
A Jus, and A Villeneuve, and J Gautier, and K Jus, and C Villeneuve, and P Pires, and R Villeneuve
August 1988, Journal of clinical psychopharmacology,
Copied contents to your clipboard!